| Nicholas Adam Isakson, CRNA | |
|
650 Huebner Rd, Fort Riley, KS 66442-4030 | |
| (785) 239-7151 | |
| (785) 240-7438 |
| Full Name | Nicholas Adam Isakson |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 650 Huebner Rd, Fort Riley, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215281548 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 618172 (Pennsylvania) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 557157 (Kansas) | Primary |
| Entity Name | Coffey County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508941865 PECOS PAC ID: 4981598653 Enrollment ID: O20040212000478 |
News Archive
Harvard Medical School researchers are working on a new, simpler way to distinguish malignant tumors from non-cancerous masses when screening for breast cancer.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Genome instability is the main risk factor in the development of tumours in humans. Understanding how, where, when and why these mutations are produced in DNA is one of the great objectives of the global scientific community.
Massachusetts regulators cut a deal Monday with insurer Health New England to limit premium increases for individual policyholders and small businesses to 8.2 percent, down from the hikes ranging from 11.5 to 21.3 percent the firm requested earlier this year, The Boston Globe reports. "With the Health New England agreement, the Patrick administration has now reached accords with five of the six Massachusetts insurance carriers that were denied double-digit increases on April 1.
Using an "Avatar"-like bio-robotic motor system that integrates a real muscle and tendon along with a computer controlled nerve stimulator acting as the avatar's spinal cord, North Carolina State University researchers have taken a giant leap closer to understanding locomotion from the leg up.
› Verified 4 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Harvard Medical School researchers are working on a new, simpler way to distinguish malignant tumors from non-cancerous masses when screening for breast cancer.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Genome instability is the main risk factor in the development of tumours in humans. Understanding how, where, when and why these mutations are produced in DNA is one of the great objectives of the global scientific community.
Massachusetts regulators cut a deal Monday with insurer Health New England to limit premium increases for individual policyholders and small businesses to 8.2 percent, down from the hikes ranging from 11.5 to 21.3 percent the firm requested earlier this year, The Boston Globe reports. "With the Health New England agreement, the Patrick administration has now reached accords with five of the six Massachusetts insurance carriers that were denied double-digit increases on April 1.
Using an "Avatar"-like bio-robotic motor system that integrates a real muscle and tendon along with a computer controlled nerve stimulator acting as the avatar's spinal cord, North Carolina State University researchers have taken a giant leap closer to understanding locomotion from the leg up.
› Verified 4 days ago
| Entity Name | Great Plains Of Cheyenne Co Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982644936 PECOS PAC ID: 7517958523 Enrollment ID: O20040519001000 |
News Archive
Harvard Medical School researchers are working on a new, simpler way to distinguish malignant tumors from non-cancerous masses when screening for breast cancer.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Genome instability is the main risk factor in the development of tumours in humans. Understanding how, where, when and why these mutations are produced in DNA is one of the great objectives of the global scientific community.
Massachusetts regulators cut a deal Monday with insurer Health New England to limit premium increases for individual policyholders and small businesses to 8.2 percent, down from the hikes ranging from 11.5 to 21.3 percent the firm requested earlier this year, The Boston Globe reports. "With the Health New England agreement, the Patrick administration has now reached accords with five of the six Massachusetts insurance carriers that were denied double-digit increases on April 1.
Using an "Avatar"-like bio-robotic motor system that integrates a real muscle and tendon along with a computer controlled nerve stimulator acting as the avatar's spinal cord, North Carolina State University researchers have taken a giant leap closer to understanding locomotion from the leg up.
› Verified 4 days ago
| Entity Name | Great Plains Of Cheyenne Co Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1992736458 PECOS PAC ID: 7517958523 Enrollment ID: O20061104000678 |
News Archive
Harvard Medical School researchers are working on a new, simpler way to distinguish malignant tumors from non-cancerous masses when screening for breast cancer.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Genome instability is the main risk factor in the development of tumours in humans. Understanding how, where, when and why these mutations are produced in DNA is one of the great objectives of the global scientific community.
Massachusetts regulators cut a deal Monday with insurer Health New England to limit premium increases for individual policyholders and small businesses to 8.2 percent, down from the hikes ranging from 11.5 to 21.3 percent the firm requested earlier this year, The Boston Globe reports. "With the Health New England agreement, the Patrick administration has now reached accords with five of the six Massachusetts insurance carriers that were denied double-digit increases on April 1.
Using an "Avatar"-like bio-robotic motor system that integrates a real muscle and tendon along with a computer controlled nerve stimulator acting as the avatar's spinal cord, North Carolina State University researchers have taken a giant leap closer to understanding locomotion from the leg up.
› Verified 4 days ago
| Entity Name | Coffey County Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1376548370 PECOS PAC ID: 4981598653 Enrollment ID: O20170317000027 |
News Archive
Harvard Medical School researchers are working on a new, simpler way to distinguish malignant tumors from non-cancerous masses when screening for breast cancer.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Genome instability is the main risk factor in the development of tumours in humans. Understanding how, where, when and why these mutations are produced in DNA is one of the great objectives of the global scientific community.
Massachusetts regulators cut a deal Monday with insurer Health New England to limit premium increases for individual policyholders and small businesses to 8.2 percent, down from the hikes ranging from 11.5 to 21.3 percent the firm requested earlier this year, The Boston Globe reports. "With the Health New England agreement, the Patrick administration has now reached accords with five of the six Massachusetts insurance carriers that were denied double-digit increases on April 1.
Using an "Avatar"-like bio-robotic motor system that integrates a real muscle and tendon along with a computer controlled nerve stimulator acting as the avatar's spinal cord, North Carolina State University researchers have taken a giant leap closer to understanding locomotion from the leg up.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Adam Isakson, CRNA 650 Huebner Rd, Fort Riley, KS 66442-4030 Ph: (785) 239-7151 | Nicholas Adam Isakson, CRNA 650 Huebner Rd, Fort Riley, KS 66442-4030 Ph: (785) 239-7151 |
News Archive
Harvard Medical School researchers are working on a new, simpler way to distinguish malignant tumors from non-cancerous masses when screening for breast cancer.
MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.
Genome instability is the main risk factor in the development of tumours in humans. Understanding how, where, when and why these mutations are produced in DNA is one of the great objectives of the global scientific community.
Massachusetts regulators cut a deal Monday with insurer Health New England to limit premium increases for individual policyholders and small businesses to 8.2 percent, down from the hikes ranging from 11.5 to 21.3 percent the firm requested earlier this year, The Boston Globe reports. "With the Health New England agreement, the Patrick administration has now reached accords with five of the six Massachusetts insurance carriers that were denied double-digit increases on April 1.
Using an "Avatar"-like bio-robotic motor system that integrates a real muscle and tendon along with a computer controlled nerve stimulator acting as the avatar's spinal cord, North Carolina State University researchers have taken a giant leap closer to understanding locomotion from the leg up.
› Verified 4 days ago
Jason A Perez, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 650 Huebner Rd., Fort Riley, KS 66442 Phone: 785-239-7667 | |
Dr. Jeffrey Burke, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 785-239-7391 | |
Phillip John Noble, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 716-359-5712 | |
Mrs. Christel Lynn Labarge Burke, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 785-802-5216 | |
Maevelyn Andalis O'donnell, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 337-378-5585 | |
Dennis W Armstrong, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 785-240-7106 |